This effect in HF and on the remaining nephrons in CKD could enhance the natriuretic efficacy and renal hemodynamic effect of SGLT2 inhibition and thereby contribute to kidney and cardio protection in nondiabetic patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.